Cover Image
市場調查報告書

乳突性甲狀腺癌:開發中產品分析

Papillary Thyroid Cancer - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 317357
出版日期 內容資訊 英文 72 Pages
訂單完成後即時交付
價格
Back to Top
乳突性甲狀腺癌:開發中產品分析 Papillary Thyroid Cancer - Pipeline Review, H2 2016
出版日期: 2016年09月30日 內容資訊: 英文 72 Pages
簡介

乳突性甲狀腺癌,是甲狀腺癌中最常見的癌症。暴露於放射線、遺傳等是風險要素,症狀是喉嚨痛,吞嚥及呼吸困難,聲音嘶啞等。治療方法有化療、放射線治療、外科的手術等。

本報告提供乳突性甲狀腺癌治療藥的開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

乳突性甲狀腺癌概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

乳突性甲狀腺癌:企業開發中的治療藥

乳突性甲狀腺癌:大學/機關研究中的治療藥

乳突性甲狀腺癌:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

乳突性甲狀腺癌:企業開發中的產品

乳突性甲狀腺癌:大學/機關研究中的產品

乳突性甲狀腺癌的治療藥開發企業

  • Exelixis, Inc.
  • Genzyme Corporation
  • Ignyta, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Plexxikon Inc.
  • Vaccinex, Inc.

乳突性甲狀腺癌:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

乳突性甲狀腺癌:最近的開發平台趨勢

乳突性甲狀腺癌:暫停中的計劃

乳突性甲狀腺癌:中止開發的產品

乳突性甲狀腺癌:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8512IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Papillary Thyroid Cancer - Pipeline Review, H2 2016, provides an overview of the Papillary Thyroid Cancer (Oncology) pipeline landscape.

Papillary thyroid cancer, also known as papillary thyroid carcinoma, is the most common form of thyroid cancer. Symptoms include throat pain, difficulty swallowing or breathing and hoarse voice. Risk factors for papillary thyroid cancer include radiation exposure and a family history of thyroid cancer. Treatment includes chemotherapy, radiation therapy and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Papillary Thyroid Cancer - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Papillary Thyroid Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Papillary Thyroid Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Papillary Thyroid Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 6, 2 and 2 respectively for Papillary Thyroid Cancer.

Papillary Thyroid Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Papillary Thyroid Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Papillary Thyroid Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Papillary Thyroid Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Papillary Thyroid Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Papillary Thyroid Cancer (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Papillary Thyroid Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Papillary Thyroid Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Papillary Thyroid Cancer Overview
  • Therapeutics Development
    • Pipeline Products for Papillary Thyroid Cancer - Overview
  • Papillary Thyroid Cancer - Therapeutics under Development by Companies
  • Papillary Thyroid Cancer - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Papillary Thyroid Cancer - Products under Development by Companies
    • Papillary Thyroid Cancer - Companies Involved in Therapeutics Development
    • Blueprint Medicines Corporation
    • Daiichi Sankyo Company, Limited
    • Ignyta, Inc.
    • Novartis AG
    • Pfizer Inc.
    • Synactix Pharmaceuticals, Inc.
    • Vaccinex, Inc.
  • Papillary Thyroid Cancer - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • BLU-667 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dabrafenib mesylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • entrectinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • everolimus - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pasireotide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PLX-7486 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PLX-8394 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RXDX-105 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sunitinib malate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SYN-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VX-15 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Papillary Thyroid Cancer - Dormant Projects
  • Papillary Thyroid Cancer - Discontinued Products
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Papillary Thyroid Cancer, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Papillary Thyroid Cancer - Pipeline by Blueprint Medicines Corporation, H2 2016
  • Papillary Thyroid Cancer - Pipeline by Daiichi Sankyo Company, Limited, H2 2016
  • Papillary Thyroid Cancer - Pipeline by Ignyta, Inc., H2 2016
  • Papillary Thyroid Cancer - Pipeline by Novartis AG, H2 2016
  • Papillary Thyroid Cancer - Pipeline by Pfizer Inc., H2 2016
  • Papillary Thyroid Cancer - Pipeline by Synactix Pharmaceuticals, Inc., H2 2016
  • Papillary Thyroid Cancer - Pipeline by Vaccinex, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Papillary Thyroid Cancer - Dormant Projects, H2 2016
  • Papillary Thyroid Cancer - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Papillary Thyroid Cancer, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top